Bone remodeling markers -- keeping a close eye on bone health

Part 1: What Are P1NP and CTX, and Why Do They Matter?

The basics: bone is always remodeling
Your skeleton is not a fixed structure. It's in a constant state of turnover — old or damaged bone is removed by cells called osteoclasts, and new bone is laid down by osteoblasts. In a healthy adult, these processes are roughly balanced. In states of net bone loss — whether from aging, hormonal changes, poor nutrition, or disuse — resorption outpaces formation. Over years, that imbalance is what leads to structural fragility and fracture.

Bone remodeling (turnover) markers (BTMs) are proteins released into the bloodstream during this process. They give us a window into the rate and direction of remodeling right now, which a static measure like DEXA bone density cannot (Schini et al., 2023).

P1NP: the formation marker
P1NP — the N-terminal propeptide of type I procollagen — is released when new collagen is incorporated into bone matrix. It's a direct byproduct of osteoblast activity. Higher P1NP generally means more active bone building. A typical reference range for women aged 50–69 is roughly 15–75 µg/L, though lab-specific ranges vary (Jenkins et al., 2013).

The International Osteoporosis Foundation and IFCC have designated serum P1NP as the reference formation marker — the one to use when you want comparable, standardized data across studies and clinical settings (Szulc et al., 2017).

CTX: the resorption marker
CTX — the C-terminal telopeptide of type I collagen — is released during degradation of mature collagen. It's a byproduct of osteoclast activity. Higher CTX means more active bone breakdown. A common reference interval is 100–700 pg/mL in women over 50, though lab ranges differ (Jenkins et al., 2013; Yuan et al., 2026).

CTX is more sensitive to diurnal variation and feeding state than P1NP — a fasting, early-morning draw is required for reliable results (Szulc et al., 2017). It's also the marker most responsive to antiresorptive medications like bisphosphonates, often falling substantially within weeks of starting treatment (Naylor et al., 2016).

Why the ratio matters
Looking at P1NP and CTX together gives you a sense of whether the skeleton is in a net building or net breakdown state. Research in orthogeriatric patients found that a P1NP/CTX ratio below 100 was independently associated with nonvertebral fractures, even after accounting for bone density (Fisher et al., 2017). A subsequent classification paper used P1NP 32 µg/L, CTX 0.250 µg/L, and a P1NP/CTX ratio of 100 to define bone turnover subtypes, noting that lower ratios indicated accelerated resorption (Fisher et al., 2018).

Using markers clinically
Current guidelines allow clinicians to use a 3-month change in CTX or P1NP as an alternative to repeat DEXA to assess treatment response or identify non-adherence (Schini et al., 2023). A fall of 25% or more in CTX by 3–6 months is generally considered an adequate response to antiresorptive therapy. For anabolic therapies, a rise of 40% or more in P1NP signals a meaningful response, with 100–200% considered excellent (Schini et al., 2023).

Higher baseline BTMs also predict fracture risk independently of BMD — so knowing where a patient starts provides useful prognostic information beyond the density number (Schini et al., 2023).

Part 2: What Moves the Markers?

Resistance and impact training
Exercise is one of the best-studied lifestyle levers for bone markers. The signal isn't uniform across all exercise types — it's specific to load and impact.

An acute crossover trial in younger and older adults found that both strength and endurance sessions temporarily shifted the P1NP/CTX ratio toward formation in the hours after exercise — though this transient effect was largely gone by 24 hours and was blunted in older participants, suggesting single sessions are insufficient and repeated loading over weeks to months is needed to see lasting BTM changes (Stunes et al., 2022).

Over training blocks, the effects are more durable. A 12-week study in older adults with low bone mass found that resistance training significantly changed CTX compared with walking, which had no effect — underscoring that load matters, not just movement (Gombos et al., 2016). A separate RCT on high-impact exercise confirmed that this type of training increases P1NP without substantially changing CTX, pointing to a formation-dominant response with appropriate loading protocols (Hilkens et al., 2023). A narrative review further summarizes that high-strain, odd-impact, and resistance protocols can produce measurable shifts in BTMs — usually an increase in P1NP with stable or reduced CTX — across weeks to months, though protocols and populations vary widely (Aini Sahrir & Kiew Ooi, 2018).

Sleep and circadian disruption
A controlled laboratory study combining three weeks of sleep restriction with circadian misalignment in healthy men found a significant decline in P1NP with no meaningful change in CTX (Swanson et al., 2017). The authors interpret this as a suppression of bone formation — not an acceleration of breakdown — as the primary mechanism by which sleep disruption affects the skeleton. The implication is that chronic sleep disruption could quietly tip the P1NP/CTX ratio toward net bone loss over time, without a clear resorption signal to catch it.

Protein and calcium
Adequate protein supports bone matrix synthesis and promotes IGF-1, a growth factor important for osteoblast function. A large cluster-randomized trial in over 7,000 older adults in residential care showed that increasing dietary calcium and protein via dairy foods over two years produced a 33% reduction in fractures and 46% fewer hip fractures — a striking clinical outcome, though this trial measured fractures and BMD rather than P1NP and CTX directly (Schini et al., 2023).

On the resorption side, calcium from food has a notable acute effect on CTX. Mechanistic work has shown that calcium-fortified foods can reduce CTX by roughly 20% within an hour and sustain a lower level over weeks (Schini et al., 2023). This gives clinicians a dietary tool that is trackable via a morning CTX draw.

Vitamin D
Vitamin D deficiency drives secondary hyperparathyroidism — elevated PTH that accelerates resorption. Many vitamin D RCTs have primarily measured PTH and BMD rather than P1NP/CTX directly, but reviews suggest modest decreases in resorption markers with supplementation, particularly when baseline status is low (Schini et al., 2023). Testing 25-OH vitamin D and intact PTH alongside CTX and P1NP gives a fuller picture of the calcium-regulation context.

The gut microbiome
Cross-sectional data in postmenopausal women show that gut microbiome composition correlates with BTM levels — certain bacterial taxa are significantly associated with lower CTX, suggesting the microbial community may influence resorption tone even at baseline (Chen et al., 2021). Reviews have further characterized the gut-bone relationship, with some taxa identified as potentially protective via lower resorption (Lyu et al., 2023; Hwang et al., 2025).

Probiotic intervention trials have produced mixed but encouraging results. A double-blind RCT in postmenopausal women with osteopenia found a significant decrease in CTX after 12 weeks of multi-species probiotic supplementation versus placebo (Yumol et al., 2025). A 2025 meta-analysis found a standardized mean difference of approximately -0.35 for CTX — modest, but directionally consistent across trials — and an average P1NP increase of about 8.4 µg/L, a small-to-moderate formation signal (Yuan et al., 2026).

The proposed mechanism centers on short-chain fatty acids, particularly butyrate, produced by gut bacteria from fermented fiber. Butyrate appears to promote regulatory T cell expansion, which in turn supports osteoblast activity via Wnt signaling in the bone marrow (Hernandez et al., 2016). Mathematical modeling of the gut-bone axis supports the idea that changes in SCFA production and immune signaling can shift resorption versus formation in ways that predict changes in CTX and P1NP, though most direct data remain preclinical (Islam et al., 2021).

What "optimal" looks like
There is no single target number that fits everyone. Clinically, the goal is directional: move CTX downward from an elevated baseline into a lower-turnover zone without over-suppressing it. Keep P1NP in a range consistent with active but not excessive formation. Watch the ratio. And re-test with the same lab, same assay, and same draw conditions — because the signal you're tracking is change over time, not any single absolute value.

References

1. Aini Sahrir N, Kiew Ooi F. Physical activity, bone remodeling and bone metabolism markers. J Exerc Sports Orthop. 2018;5(2):1–9.
   
2. Chen L, Yan S, Yang M, Yu F, Wang J, Wang X, et al. The gut microbiome is associated with bone turnover markers in postmenopausal women. Am J Transl Res. 2021;13(10):11905–17.
3. Fisher A, Fisher L, Srikusalanukul W, Smith PN. Bone turnover status: classification model and clinical implications. Int J Med Sci. 2018;15(9):955–69.
4. Fisher A, Srikusalanukul W, Fisher L, Smith PN. Lower serum P1NP/βCTX ratio and hypoalbuminemia are independently associated with osteoporotic nonvertebral fractures in older adults. Clin Interv Aging. 2017;12:1461–74.
5. Gombos GC, Bajsz V, Pék E, Schmidt B, Sió E, Molics B, et al. Direct effects of physical training on markers of bone metabolism and serum sclerostin concentrations in older adults with low bone mass. BMC Musculoskelet Disord. 2016;17:254.
6. Hernandez CJ, Guss JD, Luna M, Goldring SR. Links between the microbiome and bone. J Bone Miner Res. 2016;31(9):1638–46.
7. Hilkens L, Boerboom M, van Schijndel N, Bons J, van Loon LJC, van Dijk JW. Bone turnover following high-impact exercise is not modulated by collagen supplementation in young men: a randomized cross-over trial. Bone. 2023;168:116651.
8. Hwang D, Chong E, Li Y, Li Y, Roh K. Deciphering the gut microbiome's metabolic code: pathways to bone health and novel therapeutic avenues. Front Endocrinol. 2025;16:1553655.
9. Islam MA, Cook CV, Smith BJ, Ford Versypt AN. Mathematical modeling of the gut-bone axis and implications of butyrate treatment on osteoimmunology. Ind Eng Chem Res. 2021;60(43):15616–26.
10. Jenkins N, Black M, Paul E, Pasco JA, Kotowicz MA, Schneider HG. Age-related reference intervals for bone turnover markers from an Australian reference population. Bone. 2013;55(2):278–83.
11. Lyu Z, Hu Y, Guo Y, Liu D. Modulation of bone remodeling by the gut microbiota: a new therapy for osteoporosis. Bone Res. 2023;11:31.
12. Naylor KE, Jacques RM, Paggiosi M, et al. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study. Osteoporos Int. 2016;27(1):21–31.
13. Schini M, Vilaca T, Gossiel F, Salam S, Eastell R. Bone turnover markers: basic biology to clinical applications. Endocr Rev. 2023;44(3):417–73.
14. Stunes AK, Brobakken CL, Sujan MAJ, Mosti MP, Winther A, Syversen U, et al. Acute effects of strength and endurance training on bone turnover markers in young adults and elderly men. Front Endocrinol. 2022;13:928508.
15. Swanson CM, Shea SA, Wolfe P, Cain SW, Münch M, Vujovic N, et al. Bone turnover markers after sleep restriction and circadian disruption: a mechanism for sleep-related bone loss in humans. J Clin Endocrinol Metab. 2017;102(10):3722–30.
16. Szulc P, Naylor K, Hoyle NR, Eastell R, Leary ET; National Bone Health Alliance Bone Turnover Marker Project. Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability. Osteoporos Int. 2017;28(9):2541–56.
17. Yuan Y, Li J, Wang K, Li J, Wei H. Meta-analysis of the effects of probiotic supplementation on bone turnover markers in middle-aged and elderly patients with osteoporosis. Front Cell Infect Microbiol. 2026;15: [Epub ahead of print].
18. Yumol JL, Binda S, Nagulesapillai V, Bhardwaj R, Ward WE. Using probiotic supplementation to support bone health in postmenopausal women: a randomized, double-blind, parallel, placebo-controlled, multi-center study. Arch Osteoporos. 2025;20(1):38.